Christian Haass is a German biochemist and neuroscientist specializing in Alzheimer's disease research. His work has focused on understanding the molecular mechanisms of amyloid-beta metabolism and the role of microglia in neurodegeneration[1]. He has made significant contributions to our understanding of how genetic risk factors influence Alzheimer's disease pathogenesis and has pioneered research into immune-based therapeutic approaches. He is a leading authority on amyloid-beta metabolism and the role of microglia in Alzheimer's disease, with his work fundamentally reshaping our understanding of how immune cells contribute to neurodegeneration.
Recent PubMed-indexed publications (2024-present):
- TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism. Nature communications. 2026.
- "The DESCRIBE-ALS-FTD study: a prospective multicenter observational study of the ALS-FTD spectrum". Amyotrophic lateral sclerosis & frontotemporal degeneration. 2025.
- Image-Derived Blood Normalization of Antibody-Based TREM2 PET in Mouse Models of Amyloidosis and Myocardial Infarction. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025.
- Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques. Molecular neurodegeneration. 2025.
- The regulatory rollercoaster continues-EMA refuses donanemab. Lancet (London, England). 2025.
Haass's research has revolutionized our understanding of Alzheimer's disease pathogenesis:
- Pioneered research on the proteolytic processing of APP by secretases[1]
- Characterized the amyloidogenic pathway that generates amyloid-beta peptides
- Demonstrated how mutations in APP and presenilins cause familial Alzheimer's disease[3]
- Identified the role of alpha- and beta-secretases in amyloid processing
- Established the fundamental biochemistry of γ-secretase function and modulation
- Investigated the molecular mechanisms of amyloid-beta aggregation
- Studied the role of metal ions in amyloid fibril formation
- Explored therapeutic strategies targeting amyloid-beta oligomerization
- Researched the toxic species of amyloid-beta (oligomers vs. fibrils)[4]
- Demonstrated that soluble oligomers are the most toxic species in AD
¶ Microglia and Neuroinflammation
- Discovered that microglia undergo transformation in Alzheimer's disease[5]
- Identified the role of TREM2 in microglial function[5]
- Investigated how genetic variants in immune genes modify AD risk
- Pioneered research on the neurodegenerative microglia phenotype (DAM)[8]
- Characterized the disease-associated microglia (DAM) pathway
- Showed how TREM2 mutations impair microglial phagocytosis and clustering around amyloid plaques[7]
- Contributed to the development of secretase modulators as therapeutic agents
- Advocated for immune-based therapeutic approaches targeting microglia
- Participated in clinical trials for AD-modifying therapies
- Supported translational research from basic discoveries to clinical applications
- Haass C, et al. (1992). Amyloid beta-peptide is produced by cultured cells during normal metabolism
- De Strooper B, et al. (1998). A presenilin-1 mutation at codon 385
- Haass C, Selkoe DJ. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide
- Ulrich JD, et al. (2017). Elucidating the Role of TREM2 in Alzheimer's Disease
- Condello C, et al. (2018). Microglia constitute a barrier to neurofibrillary pathology
- Haass C, et al. (2022). TREM2 in Alzheimer's disease: from genetics to therapy
- Fischer R, et al. (2022). TREM2 deficiency impairs amyloid clearance by microglia
- Parhizkar S, et al. (2019). TREM2 deficiency leads to altered plaque morphology
¶ Awards and Honors
- Ernst Jung Prize for Science and Medicine (2000)
- Metlife Foundation Award (2002)
- Brain Prize (2018) - Awarded for his work on the immune system in Alzheimer's disease
- Gairdner International Award (2022)
- Max Planck Research Award (2015)
- Member of the German National Academy of Sciences Leopoldina
- European Academy of Sciences member
- Foreign member of the Royal Society
¶ Collaborations and Research Network
Haass maintains active collaborations with leading researchers worldwide:
- Dennis Selkoe (Harvard Medical School) - Longstanding collaboration on APP processing and amyloid biology
- Bart De Strooper (UK DRI) - Studies on presenilin and γ-secretase function
- Michele Veen (DZNE) - Microglia research and TREM2 biology
- Michael Ewers (UCSF) - Neuroimaging and biomarker studies
¶ Training and Mentorship
Throughout his career, Haass has trained numerous investigators who have established independent research programs:
- Dr. Michael Ewers (Professor, UCSF)
- Christian Haass has supervised over 30 PhD students
- Numerous postdoctoral fellows have gone on to faculty positions worldwide
Current research directions in the Haass laboratory include:
- Understanding the precise mechanisms by which TREM2 variants modify AD risk
- Developing therapeutic approaches to enhance microglial function in AD
- Investigating the intersection between amyloid and tau pathology in relation to microglial activation
- Exploring sex differences in microglial responses in Alzheimer's disease
The study of Christian Haass has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
TREM2 expression level is critical for microglial state, metabolic capacity and Alzheimer's disease pathology. Nat Commun. 2026 Jan 24.
-
Monoallelic TYROBP deletion is a novel risk factor for Alzheimer's disease. Mol Neurodegener. 2025 Apr 29.
-
The protective PLCγ2-P522R variant mitigates Alzheimer's disease-associated pathology through enhanced microglial metabolic function. J Neuroinflammation. 2025 Mar 5.
-
Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer's disease. EMBO Mol Med. 2025 Feb.
-
PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antagonist. Theranostics. 2024.
flowchart LR
subgraph Focus ["Research Focus"]
F1["Christian Haass"]
end
subgraph Contributions ["Key Contributions"]
C1["Mechanistic<br>Discovery"]
C2["Therapeutic<br>Target"]
C3["Biomarker<br>Development"]
end
F1 --> C1
F1 --> C2
F1 --> C3
C1 --> Knowledge["Disease<br>Knowledge"]
C2 --> Knowledge
C3 --> Knowledge